

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (original): An isolated Pro104 antibody that binds to Pro104 on a mammalian cell in vivo.

Claim 2 (original): The antibody of claim 1 which internalizes upon binding to Pro104 on a mammalian cell in vivo.

Claim 3 (currently amended): The antibody of ~~claim 1~~ or ~~claim 2~~ claim 1 which is a monoclonal antibody, an antibody fragment or a chimeric or humanized antibody.

Claims 4-5 (canceled)

Claim 6 (currently amended): The antibody of ~~claim 3~~ claim 1 which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5277, 6076, 6077 and 6078 or competes for binding to the same epitope as the epitope bound by a monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5277, 6076, 6077 and 6078.

Claim 7 (canceled)

Claim 8 (currently amended): The antibody of ~~claim 3~~ claim 1 which is conjugated to a growth inhibitory agent or a cytotoxic agent.

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 4

Claim 9 (canceled)

Claim 10 (currently amended): The antibody of ~~claim 9~~
claim 8 wherein the cytotoxic agent is selected from the
group consisting of toxins, antibiotics, radioactive
isotopes and nucleolytic enzymes.

Claims 11-15 (canceled)

Claim 16 (original): An anti-Pro104 monoclonal antibody
that inhibits the growth of Pro104-expressing cancer cells
in vivo.

Claims 17-18 (canceled)

Claim 19 (currently amended): The antibody of ~~claim 15~~
claim 16, which is a humanized form of an anti-Pro104
antibody produced by a hybridoma selected from the group
consisting of ATCC accession number PTA-5277, 6076, 6077 and
6078.

Claim 20 (original): The antibody of claim 16, wherein
the cancer cells are from a cancer selected from the group
consisting of breast, ovarian, pancreatic and lung cancer.

Claims 21 (canceled)

Claim 22 (currently amended): A cell that produces the
antibody of ~~claim 3~~ claim 1.

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 5

Claim 23 (original): The cell of claim 22, wherein the cell is selected from the group consisting of hybridoma cells deposited under American Type Culture Collection accession number PTA-5277, 6076, 6077 and 6078.

Claims 24-29 (canceled)

Claim 30 (currently amended): A method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with the antibody of ~~claim 1 or claim 2~~ claim 1, thereby killing the cancer cell.

Claim 31 (original): The method of claim 30, wherein the cancer cell is selected from the group consisting of breast, ovarian, pancreatic and lung cancer cell.

Claims 32-34 (canceled)

Claim 35 (currently amended): The method of claim 30, wherein the antibody is an antibody fragment or a humanized antibody.

Claim 36 (canceled)

Claim 37 (original): The method of claim 30, wherein the antibody is conjugated to a cytotoxic agent.

Claim 38 (canceled)

Claim 39 (original): The method of claim 30, wherein the antibody is a humanized form of the antibody produced by

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 6

a hybridoma selected from the group consisting of ATCC accession number PTA-5277, 6076, 6077 and 6078.

Claims 40-46 (canceled)

Claim 47 (currently amended): The method of ~~claim 46~~ claim 30, wherein the antibody is administered in conjunction with at least one chemotherapeutic agent.

Claims 48-60 (canceled)

Claim 61 (currently amended): A method for detecting Prol04 overexpression in a subject in need thereof comprising,

a) combining a serum sample of a subject with a Prol04 antibody of ~~claim 3~~ claim 1 under conditions suitable for specific binding of the Prol04 antibody to Prol04 in said serum sample

b) determining the level of Prol04 in the serum sample,

c) comparing the level of Prol04 determined in step b to the level of Prol04 in a control,

wherein an increase in the level of Prol04 in the serum sample from the subject as compared to the control is indicative of Prol04 overexpression in the subject.

Claim 62 (original): The method of claim 61 wherein the subject has cancer.

Claim 63 (original): The method of claim 62 wherein the subject has breast, ovarian, pancreatic or lung cancer or a metastatic cancer thereof.

Attorney Docket No.: DEX0491US.NP
Inventors: Papkoff et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 7

Claims 64-71 (canceled)